Tags

Type your tag names separated by a space and hit enter

Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Expert Opin Pharmacother. 2008 Mar; 9(4):601-10.EO

Abstract

Secondary hyperparathyroidism has a significant impact on morbidity and mortality due to skeletal and extraskeletal manifestations. Cinacalcet, a newly developed calcimimetic, is reported to decrease parathyroidism, as well as serum levels of phosphorus (P) and calcium (Ca) and therefore Ca x P product. Available evidence has shown that cinacalcet decreases the rate of parathyroidectomy and bone fracture in hemodialysis patients, but the death rate remains the same. Although, it is not yet available in Japan, cinacalcet is expected to be available as a possible drug for patients undergoing hemodialysis due to secondary hyperparathyroidism associated with refractory hyperphosphatemia and hypercalcemia. Except for the high cost, cinacalcet will be a welcome therapeutic option for end-stage renal disease and probably also for pre-end-stage renal disease patients. Dietary phosphate restriction and adequate hemodialysis, however, are still the main strategy for the control of hyperphosphatemia and secondary hyperparathyroidism.

Authors+Show Affiliations

University Hospital of Ryukyus, Dialysis Unit, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. chihokun@med.u-ryukyu.ac.jp

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18312161

Citation

Iseki, Kunitoshi. "Pharmacological Control of Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: Cinacalcet Is Coming to Japan." Expert Opinion On Pharmacotherapy, vol. 9, no. 4, 2008, pp. 601-10.
Iseki K. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Expert Opin Pharmacother. 2008;9(4):601-10.
Iseki, K. (2008). Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Expert Opinion On Pharmacotherapy, 9(4), 601-10. https://doi.org/10.1517/14656566.9.4.601
Iseki K. Pharmacological Control of Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: Cinacalcet Is Coming to Japan. Expert Opin Pharmacother. 2008;9(4):601-10. PubMed PMID: 18312161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. A1 - Iseki,Kunitoshi, PY - 2008/3/4/pubmed PY - 2008/3/14/medline PY - 2008/3/4/entrez SP - 601 EP - 10 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 4 N2 - Secondary hyperparathyroidism has a significant impact on morbidity and mortality due to skeletal and extraskeletal manifestations. Cinacalcet, a newly developed calcimimetic, is reported to decrease parathyroidism, as well as serum levels of phosphorus (P) and calcium (Ca) and therefore Ca x P product. Available evidence has shown that cinacalcet decreases the rate of parathyroidectomy and bone fracture in hemodialysis patients, but the death rate remains the same. Although, it is not yet available in Japan, cinacalcet is expected to be available as a possible drug for patients undergoing hemodialysis due to secondary hyperparathyroidism associated with refractory hyperphosphatemia and hypercalcemia. Except for the high cost, cinacalcet will be a welcome therapeutic option for end-stage renal disease and probably also for pre-end-stage renal disease patients. Dietary phosphate restriction and adequate hemodialysis, however, are still the main strategy for the control of hyperphosphatemia and secondary hyperparathyroidism. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18312161/Pharmacological_control_of_secondary_hyperparathyroidism_in_chronic_hemodialysis_patients:_cinacalcet_is_coming_to_Japan_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.9.4.601 DB - PRIME DP - Unbound Medicine ER -